Paula J.  Swain net worth and biography

Paula Swain Biography and Net Worth

EVP of Incyte
Paula Swain joined Incyte in January 2002 and serves as Executive Vice President of Human Resources. Before joining the company, Ms. Swain spent nearly 10 years with DuPont (acquired by Bristol-Myers Squibb Company in 2001), where she served as Vice President and Senior Vice President of Human Resources. She has also held human resource planning and employee relations positions with Chase Manhattan Bank, Marine Midland Bank, and Delaware Trust Company. Ms. Swain received her BA in psychology from Rockhurst College and graduated from the strategic human resources planning program at Harvard Business School.

What is Paula J. Swain's net worth?

The estimated net worth of Paula J. Swain is at least $2.86 million as of March 31st, 2020. Ms. Swain owns 50,132 shares of Incyte stock worth more than $2,856,020 as of March 29th. This net worth estimate does not reflect any other investments that Ms. Swain may own. Additionally, Ms. Swain receives an annual salary of $611,920.00 as EVP at Incyte. Learn More about Paula J. Swain's net worth.

How old is Paula J. Swain?

Ms. Swain is currently 66 years old. There are 8 older executives and no younger executives at Incyte. The oldest executive at Incyte is Ms. Pamela M. Murphy, Vice President of Investor Relations & Corporate Communications, who is 73 years old. Learn More on Paula J. Swain's age.

What is Paula J. Swain's salary?

As the EVP of Incyte Co., Ms. Swain earns $611,920.00 per year. There are 4 executives that earn more than Ms. Swain. The highest earning executive at Incyte is Mr. Herve Hoppenot, CEO & Chairman, who commands a salary of $2,890,000.00 per year. Learn More on Paula J. Swain's salary.

How do I contact Paula J. Swain?

The corporate mailing address for Ms. Swain and other Incyte executives is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. Incyte can also be reached via phone at (302) 498-6700 and via email at [email protected]. Learn More on Paula J. Swain's contact information.

Has Paula J. Swain been buying or selling shares of Incyte?

Paula J. Swain has not been actively trading shares of Incyte during the past quarter. Most recently, Paula J. Swain sold 10,870 shares of the business's stock in a transaction on Friday, January 7th. The shares were sold at an average price of $73.31, for a transaction totalling $796,879.70. Learn More on Paula J. Swain's trading history.

Who are Incyte's active insiders?

Incyte's insider roster includes Dashyant Dhanak (EVP), Jonathan Dickinson (EVP), Wendy Dixon (Director), Barry Flannelly (EVP), Herve Hoppenot (President), Vijay Iyengar (EVP), Michael Morrissey (EVP), Maria Pasquale (EVP), Steven Stein (EVP), Paula Swain (EVP), Thomas Tray (Insider), and Wenquing Yao (EVP). Learn More on Incyte's active insiders.

Are insiders buying or selling shares of Incyte?

During the last twelve months, insiders at the biopharmaceutical company sold shares 2 times. They sold a total of 867 shares worth more than $54,750.60. The most recent insider tranaction occured on January, 2nd when EVP Vijay K Iyengar sold 657 shares worth more than $42,705.00. Insiders at Incyte own 17.5% of the company. Learn More about insider trades at Incyte.

Information on this page was last updated on 1/2/2024.

Paula J. Swain Insider Trading History at Incyte

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/7/2022Sell10,870$73.31$796,879.70View SEC Filing Icon  
3/31/2020Sell2,329$71.44$166,383.7650,132View SEC Filing Icon  
2/19/2020Sell2,500$80.00$200,000.0050,993View SEC Filing Icon  
1/15/2020Sell2,500$81.12$202,800.0044,112View SEC Filing Icon  
12/16/2019Sell2,500$91.61$229,025.0044,112View SEC Filing Icon  
11/15/2019Sell2,500$86.46$216,150.0044,112View SEC Filing Icon  
10/22/2019Sell2,500$80.00$200,000.0044,112View SEC Filing Icon  
9/18/2019Sell2,500$80.00$200,000.0044,112View SEC Filing Icon  
8/15/2019Sell2,500$80.96$202,400.0044,112View SEC Filing Icon  
7/15/2019Sell2,500$80.00$200,000.0044,751View SEC Filing Icon  
6/17/2019Sell2,500$80.00$200,000.0039,013View SEC Filing Icon  
4/1/2019Sell10,000$87.01$870,100.0038,295View SEC Filing Icon  
3/1/2019Sell10,000$86.68$866,800.00View SEC Filing Icon  
2/1/2019Sell10,000$81.19$811,900.0041,124View SEC Filing Icon  
1/4/2019Sell30,000$70.00$2,100,000.0062,324View SEC Filing Icon  
9/4/2018Sell10,000$73.21$732,100.00View SEC Filing Icon  
8/21/2018Sell10,000$70.00$700,000.0042,324View SEC Filing Icon  
4/30/2018Sell80,000$62.43$4,994,400.0039,467View SEC Filing Icon  
8/31/2017Sell20,000$140.00$2,800,000.0055,067View SEC Filing Icon  
10/20/2016Sell10,000$90.00$900,000.0039,248View SEC Filing Icon  
9/23/2016Sell20,000$90.00$1,800,000.0049,248View SEC Filing Icon  
7/29/2016Sell60,000$90.00$5,400,000.0089,248View SEC Filing Icon  
1/15/2016Sell13,531$76.96$1,041,345.7623,693View SEC Filing Icon  
2/17/2015Sell17,500$76.90$1,345,750.00View SEC Filing Icon  
1/20/2015Sell17,500$74.17$1,297,975.00View SEC Filing Icon  
1/5/2015Sell17,500$73.90$1,293,250.00View SEC Filing Icon  
9/5/2013Sell94,444$35.06$3,311,206.64View SEC Filing Icon  
See Full Table

Paula J. Swain Buying and Selling Activity at Incyte

This chart shows Paula J Swain's buying and selling at Incyte by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Incyte Company Overview

Incyte logo
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; and in-license agreements with Agenus, Merus, MacroGenics, and Syndax. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Read More

Today's Range

Now: $56.97
Low: $56.61
High: $57.33

50 Day Range

MA: $59.13
Low: $56.55
High: $61.87

2 Week Range

Now: $56.97
Low: $50.27
High: $76.04

Volume

1,883,106 shs

Average Volume

1,735,741 shs

Market Capitalization

$12.79 billion

P/E Ratio

21.50

Dividend Yield

N/A

Beta

0.65